BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23735618)

  • 1. Canine melanoma diagnosis: RACK1 as a potential biological marker.
    Campagne C; Julé S; Alleaume C; Bernex F; Ezagal J; Château-Joubert S; Estrada M; Aubin-Houzelstein G; Panthier JJ; Egidy G
    Vet Pathol; 2013 Nov; 50(6):1083-90. PubMed ID: 23735618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-kit expression in canine mucosal melanomas.
    Newman SJ; Jankovsky JM; Rohrbach BW; LeBlanc AK
    Vet Pathol; 2012 Sep; 49(5):760-5. PubMed ID: 21825314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RACK1, a clue to the diagnosis of cutaneous melanomas in horses.
    Campagne C; Julé S; Bernex F; Estrada M; Aubin-Houzelstein G; Panthier JJ; Egidy G
    BMC Vet Res; 2012 Jun; 8():95. PubMed ID: 22747534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of tenascin in melanocytic tumours of dogs.
    Sevastre B; van Ederen AM; Terlou M; Gruys E; Nederbragt H
    J Comp Pathol; 2007 Jan; 136(1):49-56. PubMed ID: 17258226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.
    King R; Weilbaecher KN; McGill G; Cooley E; Mihm M; Fisher DE
    Am J Pathol; 1999 Sep; 155(3):731-8. PubMed ID: 10487831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fascin-1 expression in canine cutaneous and oral melanocytic tumours.
    Yamada N; Mori T; Murakami M; Noguchi S; Sakai H; Akao Y; Maruo K
    Vet Comp Oncol; 2012 Dec; 10(4):303-11. PubMed ID: 22236355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of prognostic significance of angiogenesis in canine melanocytic tumours.
    Cuitiño MC; Massone AR; Idiart JR
    J Comp Pathol; 2012; 147(2-3):147-52. PubMed ID: 22520819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcription analysis in the MeLiM swine model identifies RACK1 as a potential marker of malignancy for human melanocytic proliferation.
    Egidy G; Julé S; Bossé P; Bernex F; Geffrotin C; Vincent-Naulleau S; Horak V; Sastre-Garau X; Panthier JJ
    Mol Cancer; 2008 Apr; 7():34. PubMed ID: 18442364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E-Cadherin Expression in Canine Melanocytic Tumors: Histological, Immunohistochemical, and Survival Analysis.
    Silvestri S; Porcellato I; Mechelli L; Menchetti L; Iussich S; De Maria R; Sforna M; Bongiovanni L; Brachelente C
    Vet Pathol; 2020 Sep; 57(5):608-619. PubMed ID: 32578507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions.
    Nielsen PS; Riber-Hansen R; Steiniche T
    Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FoxP3 and IDO in Canine Melanocytic Tumors.
    Porcellato I; Brachelente C; De Paolis L; Menchetti L; Silvestri S; Sforna M; Vichi G; Iussich S; Mechelli L
    Vet Pathol; 2019 Mar; 56(2):189-199. PubMed ID: 30381008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microphthalmia transcription factor immunohistochemistry: a useful diagnostic marker in the diagnosis and detection of cutaneous melanoma, sentinel lymph node metastases, and extracutaneous melanocytic neoplasms.
    O'Reilly FM; Brat DJ; McAlpine BE; Grossniklaus HE; Folpe AL; Arbiser JL
    J Am Acad Dermatol; 2001 Sep; 45(3):414-9. PubMed ID: 11511840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs.
    Roels S; Tilmant K; Ducatelle R
    J Comp Pathol; 1999 Jul; 121(1):13-24. PubMed ID: 10373290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
    Nazarian RM; Prieto VG; Elder DE; Duncan LM
    J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of c-kit immunoexpression in canine cutaneous melanocytic tumors.
    Gomes J; Queiroga FL; Prada J; Pires I
    Melanoma Res; 2012 Jun; 22(3):195-201. PubMed ID: 22407004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours.
    Pires I; Garcia A; Prada J; Queiroga FL
    J Comp Pathol; 2010; 143(2-3):142-9. PubMed ID: 20207364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma.
    Laprie C; Abadie J; Amardeilh MF; Net JL; Lagadic M; Delverdier M
    Vet Dermatol; 2001 Jun; 12(3):139-47. PubMed ID: 11420929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
    Gleason BC; Nascimento AF
    Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.